New drug combo may boost standard liver cancer procedure

NCT ID NCT04712643

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) to a standard liver cancer procedure called TACE helps people with untreated liver cancer live longer or delay the cancer from getting worse. About 342 adults with liver cancer who are not candidates for curative treatments will be randomly assigned to receive either TACE alone or TACE plus the drug combination. The goal is to see if the combination improves survival and delays the need for more intensive treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Aichi Cancer Center

Aichi, 464-8681, Japan
Anhui Provincial Hospital

Anhui, 230001, China
Beijing Tsinghua Changgung Hospital

Beijing, 102218, China
Beijing You An Hospital

Beijing, 100069, China
Chiba University Hospital

Chiba, 260-8677, Japan
Fudan University Shanghai Cancer Center

Shanghai, 200120, China
Fujian Cancer Hospital

Fuzhou, 350014, China
Guangxi Cancer Hospital of Guangxi Medical University

Nanning, 530021, China
Harbin Medical University Cancer Hospital

Harbin, 150081, China
Henan Cancer Hospital

Zhengzhou, 450008, China
Hiroshima University Hospital

Hiroshima, 734-8551, Japan
Hunan Cancer Hospital

Changsha, 410013, China
Jiangsu Cancer Hospital

Nanjing, 210009, China
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)

Nanjing, 210029, China
Kanagawa Cancer Center

Kanagawa, 241-8515, Japan
Kindai University Hospital

Osaka, 589-8511, Japan
Kitasato University Hospital

Kanagawa, 252-0375, Japan
Kurume University Hospital

Fukuoka, 830-0011, Japan
Mengchao Hepatobiliary Hospital Of Fujian Medical University

Fuzhou, 350025, China
Nanfang Hospital, Southern Medical University

Guangzhou, 510515, China
Peking University First Hospital

Beijing, 100034, China
Peking University People's Hospital

Beijing, 100044, China
Renji Hospital Shanghai Jiaotong University School of Medicine

Shanghai, 200127, China
Shengjing Hospital of China Medical University

Shenyang, 110004, China
Southwest Hospital , Third Military Medical University

Chongqing, 400038, China
Sun Yet-sen University Cancer Center

Guangzhou, 510060, China
The 900th Hospital of PLA joint service support force

Fuzhou, 110016, China
The First Affiliate Hospital of Guangxi Medical University

Nanning, 530021, China
The First Affiliated Hospital Of Fujian Medical University

Fuzhou, 350005, China
The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, China
The First Affiliated Hospital, Chongqing Medical University

Chongqing, 400016, China
The University of Osaka Hospital

Osaka, 565-0871, Japan
Tianjin Cancer Hospital

Tianjin, 300060, China
Toranomon Hospital

Tokyo, 105-8470, Japan
West China Hospital, Sichuan University

Chengdu, China
Xi'an Inernational Medical Center Hospital

Xi'an, China
Yokohama City University Medical Center

Kanagawa, 232-0024, Japan
Zhejiang Cancer Hospital

Hangzhou, 310022, China
Zhongshan Hospital Fudan Unvierstiy

Shanghai, China
Zhuhai People's Hospital

Zhuhai, 519099, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.